90Y and 111In Complexes of a DOTA-Conjugated Integrin αvβ3 Receptor Antagonist: Different but Biologically Equivalent

Bioconjugate Chemistry

Volumn 15, Issue 2, 2004, Pages 235-241

  Onthank, David C ^a   Liu, Shuang ^a,b   Silva, Paula J ^a   Barrett, John A ^a,c   Harris, Thomas D ^a   Robinson, Simon P ^a   Edwards, D Scott ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b PURDUE UNIVERSITY   (United States)

^c EPIX Medical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOSIMETRY; ENDOTHELIAL CELLS; METAL IONS; METALS;

ANIMAL MODEL; ENDOTHELIAL-CELLS; HIGH AFFINITY; HIGH SPECIFICITY; INTEGRINS; NONPEPTIDE; RECEPTOR ANTAGONISTS; RETENTION TIME; THERAPEUTIC EFFECTS; TUMOUR CELLS;

TUMORS;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANTINEOPLASTIC AGENT; COORDINATION COMPOUND; INDIUM 111; RADIOPHARMACEUTICAL AGENT; TA 138; TA 138 Y 90; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; VITRONECTIN RECEPTOR ANTAGONIST; YTTRIUM 90; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; INDIUM; SINGLE HETEROCYCLIC RINGS; SULFONAMIDE; YTTRIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOEQUIVALENCE; BREAST TUMOR; CONTROLLED STUDY; DOSIMETRY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG TUMOR LEVEL; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHILICITY; ISOTOPE LABELING; MOUSE; NONHUMAN; ONCOGENE NEU; TUMOR CELL; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; GENETICS; METABOLISM; PHARMACOKINETICS; PROTO ONCOGENE; TISSUE DISTRIBUTION; TRANSGENIC MOUSE;

ANIMALIA;

ANIMALS; DISEASE MODELS, ANIMAL; GENES, ERBB-2; HETEROCYCLIC COMPOUNDS, 1-RING; INDIUM RADIOISOTOPES; INTEGRIN ALPHAVBETA3; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; SULFONAMIDES; THERAPEUTIC EQUIVALENCY; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 1642395737     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc034108q     Document Type: Article

References (49)

1. Reubi, J. C. (1997) Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Quart. J. Nucl. Med. 41, 63-70.
2. Volkert, W. A. and Hoffman, T. J. (1999) Therapeutic radiopharmaceuticals. Chem. Rev. 99, 2269-2292.
3. Kwekkeboom, D., Krenning, E. P., and de Jong, M. (2000) Peptide receptor imaging and therapy. J. Nucl. Med. 41, 1704-1713.
4. Boerman, O. C., Oyen, W. J. G., and Corstens, F. H. M. (2000) Radiol-labeled receptor-binding peptides: A new class of radiopharmaceuticals. Semin. Nucl. Med. 30, 195-208.
5. Liu, S., and Edwards, D. S. (2001) Bifunctional chelators for target specific therapeutic lanthanide radiopharmaceuticals. Bioconjugate Chem. 12, 7-34.
6. Signore, A., Annovazzi, A., Chianelli, M., Coretti, F., Van de Wiele, C., Watherhouse, R. N., and Scopinaro, F. (2001) Peptide radiopharmaceuticals for diagnosis and therapy. Eur. J. Nucl. Med. 28, 1555-1565.
7. Liu, S., and Edwards, D. S. (2002) Fundamentals of receptor-based diagnostic metalloradiopharmaceuticals. Topics Curr. Chem. 222, 259-278.
8. Jong, M., Kwekkeboom, D., Valkema, R., and Krenning, E. P. (2003) Radiolabeled Peptides for tumor therapy: current status and future directions. Eur. J. Nucl. Med. 30, 463-469.
9. Fichna, J., and Janecka, A. (2003) Synthesis of target-specific radiolabeled peptides for diagnostic imaging. Bioconjugate Chem. 14, 3-17.
10. 3 directed radiopharmaceuticals for tumor imaging. Drugs Future 28, 551-564.
11. Moi, M. K., Meares, C. F., McCall, M. J., Cole, W. C., and DeNardo, S. J. (1985) Copper chelates as probes of biological systems: stable copper complexes with macrocyclic bifunctional chelating agent. Anal. Chem. 148, 249-253.
12. Moi, M. K., and Meares, C. F. (1988) The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′N″, N‴-tetraacetic acid and study of its yttrium(III) complex. J. Am. Chem. Soc. 110, 6266-6267.
13. Kline, S. J., Betebenner, D. A., and Johnson, D. K. (1991) Carboxymethyl-substituted bifunctional chelators: preparation of aryl isothionate derivatives of 3-(carboxymethyl)-3-azapentanedioic acid, 3, 12-bis(carboxymethyl)-6,9-dioxa-3,12-diazatetradecanedioic acid, and 1, 4,7,10-tetraazacyclo-dodecane-N,N′N″,N‴-tetraacetic acid for use as protein labels. Bioconjugate Chem. 2, 26-31.
14. Li, M., and Meares, C. F. (1993) Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconjugate Chem. 4, 275-283.
15. Lewis, M. R., Raubitschek, A., and Shively, J. E. (1994) A facile, water soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. Bioconjugate Chem. 5, 565-576.
16. Kulis, D. L., DeNardo, S. J., DeNardo, G. L., O'Donnell, R. T., and Meares, C. F. (1998) Optimized conditions for chelation of yittrium-90-DOTA immunoconjugates. J. Nucl. Med. 39, 2105-2110.
17. Lewis, M. R., and Shively, J. E. (1998) Maleimidocycteine-amido-DOTA derivatives: New reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions. Bioconjugate Chem. 9, 72-86.
18. Heppler, A., Froidevaux, S., Mäcke, H. R., Jermann, E., Béhé, M., Powell, P., and Hennig, M. (1999) Radiometal-labeled macrocyclic chelator-derived somatostatin analogue with superb tumor-targeting properties and potential for receptor-mediated internal therapy. Chem. Eur. J. 5, 1974-1981.
19. 3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. J. Nucl. Med. 40, 2081-2087.
20. Reubi, J. C., Waser, B., Schaer, J. C., Laederach, U., Erion, J., Srinivasam, A., Schmidt, M. A., and Bugaj, J. E. (1998) Unsulfated DTPA- and DOTA-CCK analogs as specific high affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur. J. Nucl. Med. 25, 481-490.
21. Behr, T. M., Jenner, N., Béhé, M., Angerstein, C., Gratz, S., Raue, F., and Becker, W. (1999) Radiolabeled peptides for targeting cholecystokinin-B-gastrin receptor-expressing tumors. J. Nucl. Med. 40, 1029-1040.
22. Behr, T. M., Jenner, N., Béhé, M., Angerstein, C., Gratz, S., Raue, F., and Becker, W. (1999) Cholecystokinin-B-gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin. Cancer Res. 5, 3124s-3138s.
23. 177Lu-labeling of a DOTA-conjugated vitronectin receptor antagonist for tumor therapy. Bioconjugate Chem. 12, 559-568.
24. 90Y-labeled DOTA-biomolecule conjugates using gentisic and ascorbic acid. Bioconjugate Chem. 12, 554-558.
25. 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. J. Nucl. Med. 40, 268-276.
26. Canera, L., Kinuya, S., Garmestani, K., Brechbiel, M. W., Wu, C., Pai, L. H., McMurry, T. J., Gansow, O. A., Pastan, I., Paik, C. H., and Carrasquillo, J. A. (1994) Comparative biodistribution of indium- and yttrium-labeled B3 monoalonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz-)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA). Eur. J. Nucl. Med. 21, 640-646.
27. 90Y-labeled analogue. Eur. J. Nucl. Med. 26, 358-366.
28. 99m-Tc-Labeling of a hydrazinonictotinamide-conjugated vitronectin receptor antagonist. Bioconjugate Chem. 12, 624-629.
29. 90Y-labeled DTPA-biomolecule conjugates. Bioconjugate Chem. 2001, 12, 84-91.
30. 111In labeled DTPA-peptide conjugates. Bioconjugate Chem. 12, 630-634.
31. Janssen, M., Oyen, W. J. G., Massuger, L. F. A. G., Frielink, C., Dijkgraaf, I., Edwards, D. S., Rajopadyhe, M., Corsten, F. H. M., and Boerman, O. C. Tumor targeting with radio-labeled alpha(v)beta(3) integrin binding peptides in nude mouse model. Cancer Res 2002, 62, 6146-6151.
32. 177Lu-labeling of a DOTA-conjugated nonpeptide vitronectin receptor antagonist. Bioconjugate Chem. 14, 1030-1037.
33. 3 antagonists for tumor imaging and radiotherapy. Cancer Biother. Radiopharm. 18, 627-641.
34. Currie, L. A. (1968) Limits for qualitative detection and quantitative determination. Anal. Chem. 40, 586-593.
35. 111In-labeled DOTA-biomolecule conjugates. Bioconjugate Chem. 13, 902-913.
36. Maeke, H., Scherer, G., Heppeler, A., and Henig, M. (2001) Is In-111 an ideal surrogate for Y-90? If not, why? Eur. J. Nucl. Med. 28, 967 (abstract no. OS-27).
37. 111In-labeled DOTA-biomolecule conjugates. Inorg. Chem. 42, 559-568.
38. Aime, S., Botta, M., and Ermodi, G. (1992) NMR study of solution structures and dynamics of lanthanide(III) complexes of DOTA. Inorg. Chem. 31, 4291-4299.
39. Aime, S., Anelli, P. L., Botta, M., Fedeli, F., Ermondi, G., Grandi, M., Paoli, P., and Uggeri, F. (1992) Synthesis, characterization, and 1/T1 NMRD profiles of gadolinium(III) complexes of monoamide derivatives of DOTA-like ligands. X-ray structure of the 10-[2-[[2-hydroxy-1-(hydroxymethyl)-ethyl]amino]-1-(phenylmethoxy)methyl] 2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid-gadolinium(III) complex. Inorg. Chem. 31, 2422-2428.
40. Aime, S., Botta, M., Ermondi, G., Terreno, E., Anelli, P. L., Dedeli, F., and Uggeri, F. (1996) Relaxometric, structural, and dynamic NMR studies of DOTA-like Ln(III) complexes (Ln = La, Gd, Ho, Yb) containing a p-nitrophenyl substituent. Inorg. Chem. 35, 2726-2736.
41. Kumar, K., Chang, C. A., Francesconi, L. C., Dischino, D. D., Malley, M. F., Cougoutas, J. Z., and Tweedle, M. F. (1994) Synthesis, stability, and structure of gadolinium(III) and yttrium(III) macrocyclic poly(amino carboxylates). Inorg. Chem. 33, 3567-3575.
42. Shannon, R. D. (1976) Revised effective ionic radii and systemic studies of interatomic distances in halides and chalogenides. Acta Crystallogr. A32, 751-767.
43. 3) schiff base and aminephenol ligands: influence of rigidity and preorganization of ligands on compound structure. Inorg. Chem. 34, 2164-2178.
44. 3 amine phenol ligands for group 13 Metal Ions: Evidence for intrastrand and interstrand hrdrogen bonds in polydentate amine phenols. Inorg. Chem. 32, 4268-4276.
45. 3) tripodal amine phenol ligand complexes of aluminum, gallium and indium. Inorg. Chem. 32, 1756-1765.
46. 3) amine phenol ligands. Inorg. Chem. 31, 5400-5407.
47. 3+ complexes with relavance to radiopharmaceutical applications. J. Chem. Soc., Chem. Commun. 460-462.
48. Mäcke, H. R., Riesen, A., and Ritter, W. (1989) The molecular structure of indium-DTPA. J. Nucl. Med. 30, 1235-1239.
49. Malyrick M. A., Ilyhin, A. B., and Petrosyans, S. P. (1994) Seven- and eight-coordinate complexes of indium(III) with nitrilotriacetic acid. Main Group Metal Chem. 17, 707-717.